---
title: "Hanx Biopharmaceuticals Proposes General Mandate to Repurchase H Shares at Upcoming EGM"
description: "Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has proposed a general mandate to repurchase H shares, which will be voted on at an extraordinary general meeting on February 12, 2026. Shareholders are encour"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273874953.md"
published_at: "2026-01-27T17:20:12.000Z"
---

# Hanx Biopharmaceuticals Proposes General Mandate to Repurchase H Shares at Upcoming EGM

> Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has proposed a general mandate to repurchase H shares, which will be voted on at an extraordinary general meeting on February 12, 2026. Shareholders are encouraged to seek professional advice regarding their voting decisions.

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has proposed granting a general mandate to repurchase H shares, which will be put to a shareholder vote at an extraordinary general meeting scheduled for February 12, 2026. Shareholders are advised to consult their professional advisers regarding how to vote on the proposal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002794), on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03378.HK - HANXBIO-B](https://longbridge.com/en/quote/03378.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hanx Biopharmaceuticals Sets Out Board and Committee Structure | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, includin | [Link](https://longbridge.com/en/news/275228301.md) |
| Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111 | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has initiated a Phase I clinical trial for HX111, an OX40-targeting antibody-dr | [Link](https://longbridge.com/en/news/274815164.md) |
| DHS is hunting for any US citizens who may have voted before being naturalized | The Department of Homeland Security (DHS) is intensifying investigations into potential voter fraud, focusing on U.S. ci | [Link](https://longbridge.com/en/news/276376670.md) |
| KUB Coin (KUB) - Validators Vote - 20 Feb–08 Mar 2026 | KUB Chain is conducting a governance vote on the proposal for "Single-Tier Validators for Lowering Barriers & Boosting E | [Link](https://longbridge.com/en/news/276434774.md) |
| Aarvi Encon Publishes Postal Ballot and E-Voting Details for Shareholders | Aarvi Encon Ltd. has announced the dispatch of its postal ballot notice and remote e-voting details to shareholders, com | [Link](https://longbridge.com/en/news/276322903.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.